No genetic association between postsynaptic density-95 gene polymorphisms and schizophrenia

Neuroscience Letters

Volumn 400, Issue 1-2, 2006, Pages 168-171

  Kawashima, Ritsuko ^a   Ohnuma, Tohru ^a   Shibata, Nobuto ^a   Arai, Heii ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

NMDA receptor; Polymorphism; PSD 95; Schizophrenia

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POSTSYNAPTIC DENSITY PROTEIN 95;

ADULT; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NERVE CELL PLASTICITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; RISK ASSESSMENT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC;

EID: 33646146466     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.02.036     Document Type: Article

References (20)

1. Bulayeva K.B., Leal S.M., Pavlova T.A., Kurbonov R.M., Glatt S.J., Bulayev O.A., and Tsuang M.T. Mapping genes of complex psychiatric disease in Daghestan genetic isolates. Am. J. Med. Genet. B Neuropsychiatr. Genet. 132 (2005) 76-84
2. Deakin J.F., Slater P., Simpson M.D., Gilchrist A.C., Skan W.J., Royston M.C., Reynolds G.P., and Cross A.J. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 52 (1989) 1781-1786
3. Ishimaru M., Kurumaji A., and Toru M. NMDA-associated glycine binding site increases in schizophrenic brains. Biol. Psychiatry 32 (1992) 379-381
4. Ishimaru M., Kurumaji A., and Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol. Psychiatry 35 (1994) 84-95
5. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatry 9 (1987) 12-35
6. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
7. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., and Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 151 (1994) 1234-1236
8. Kajimoto Y., Shirakawa O., Lin X.H., Hashimoto T., Kitamura N., Murakami N., Takumi T., and Maeda K. Synapse-associated protein 90/postsynaptic density-95-associated protein (SAPAP) is expressed differentially in phencyclidine-treated rats and is increased in the nucleus accumbens of patients with schizophrenia. Neuropsychopharmacology 28 (2003) 1831-1839
9. Kornhuber J., Mack-Burkhardt F., Riederer P., Hebenstreit G.F., Reynolds G.P., Andrews H.B., and Beckmann H. [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J. Neural. Transm. 77 (1989) 231-236
10. Mueller H.T., Haroutunian V., Davis K.L., and Meador-Woodruff J.H. Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Mol. Brain Res. 121 (2004) 60-69
11. Nishikawa T., Takashima M., and Toru M. Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci. Lett. 40 (1983) 245-250
12. Ohnuma T., Augood S.J., Arai H., McKenna P.J., and Emson P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol. Brain Res. 56 (1998) 207-217
13. Ohnuma T., Kato H., Arai H., Faull R.L., McKenna P.J., and Emson P.C. Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia. Neuroreport 11 (2000) 3133-3137
14. Ohnuma T., Kato H., Arai H., McKenna P.J., and Emson P.C. Expression of Fyn, a non-receptor tyrosine kinase in prefrontal cortex from patients with schizophrenia and its correlation with clinical onset. Mol. Brain Res. 112 (2003) 90-94
15. Ohnuma T., Shibata N., Matsubara Y., Sato S., Yamashina M., and Arai H. No genetic association between polymorphisms in the Fyn kinase gene and age of schizophrenic onset. Neurosci. Lett. 343 (2003) 70-72
16. Park N., Juo S.H., Cheng R., Liu J., Loth J.E., Lilliston B., Nee J., Grunn A., Kanyas K., Lerer B., Endicott J., Gilliam T.C., and Baron M. Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia. Mol. Psychiatry 9 (2004) 1091-1099
17. Simpson M.D., Slater P., Royston M.C., and Deakin J.F. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr. Res. 6 (1991) 41-48
18. Toro C., and Deakin J.F. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr. Res. 15 (2005) 323-330
19. Toyooka K., Iritani S., Makifuchi T., Shirakawa O., Kitamura N., Maeda K., Nakamura R., Niizato K., Watanabe M., Kakita A., Takahashi H., Someya T., and Nawa H. Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia. J. Neurochem. 83 (2002) 797-806
20. Waziri R. Glycine therapy of schizophrenia. Biol. Psychiatry 23 (1988) 210-211